Kala Bio Secures Exclusive U.S. Distribution Deal for Ophthalmology Genetic Testing — KALA BIO, Inc.

Event summary

Kala Bio and Virotek finalized an exclusive U.S. distribution agreement for ophthalmology genetic testing, effective September 4, 2026.
Kala Bio gains exclusive rights to market, promote, distribute, and resell Virotek's ophthalmology genomic program for an initial one-year term.
The deal includes a right of first refusal for Kala Bio on certain ophthalmology products and services, and potential expansion into oncology and preventive-health verticals.
The U.S. genetic testing market was valued at $5.7 billion in 2025 and is projected to reach $6.9 billion in 2026.

The big picture

This partnership aligns with Kala Bio's strategy of building operating scale through staged transactions, focusing on capital efficiency and long-term growth. The deal positions Kala Bio to tap into the growing U.S. genetic testing market, particularly in ophthalmology, while also setting the stage for potential expansion into larger patient populations through oncology and preventive-health verticals.

What we're watching

Execution Risk: Whether Kala Bio can achieve the agreed commercial milestones to maintain exclusivity under the agreement.
Market Expansion: The pace at which Kala Bio and Virotek can expand into additional clinical verticals, including oncology and preventive health.
Operational Scale: How Kala Bio's capital allocation strategy of staged, capital-efficient partnerships will impact its long-term growth and operational scale.